Zhao Yang, Peng Jing, Zhang Enlong, Jiang Ning, Li Jiang, Zhang Qi, Zhang Xuening, Niu Yuanjie
Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Sex Hormone Research Center, Tianjin Institute of Urology, Tianjin 300211, China.
Oncotarget. 2016 Mar 1;7(9):10023-36. doi: 10.18632/oncotarget.7054.
We performed a meta-analysis of CD133-related clinical data to investigate the role of cancer stem cells (CSCs) in the clinical outcomes of colorectal cancer (CRC) patients, analyzing the effectiveness of various therapeutic strategies and examining the validity of the CSC hypothesis. For 28 studies (4546 patients), the relative risk (RR) to survival outcomes associated with CD133+ CRCs were calculated using STATA 12.0 software. Pooled results showed that CD133High patients had poor 5-year overall survival (RR 0.713, 95% CI 0·616-0·826) and 5-year disease free survival (RR 0·707, 95% CI 0·602-0·831). Both associations were consistently observed across different races, research techniques and therapeutic strategies. In a subgroup receiving adjuvant therapy, CD133Low patients achieved significantly better survival than CD133High patients. The findings suggest that CD133 could serve as a predictive marker of poor prognosis and treatment failure in CRC. CD133Low patients could benefit from adjuvant treatments, while CD133High patients should be given novel treatments besides adjuvant therapy. Our results also provide evidence in support of the CSC hypothesis.
我们对CD133相关的临床数据进行了荟萃分析，以研究癌症干细胞（CSCs）在结直肠癌（CRC）患者临床结局中的作用，分析各种治疗策略的有效性，并检验CSC假说的正确性。对于28项研究（4546例患者），使用STATA 12.0软件计算与CD133+ CRC相关的生存结局的相对风险（RR）。汇总结果显示，CD133高表达患者的5年总生存率较差（RR 0.713，95%CI 0·616 - 0·826），5年无病生存率也较差（RR 0·707，95%CI 0·602 - 0·831）。在不同种族、研究技术和治疗策略中均一致观察到这两种关联。在接受辅助治疗的亚组中，CD133低表达患者的生存率明显高于CD133高表达患者。研究结果表明，CD133可作为CRC预后不良和治疗失败的预测标志物。CD133低表达患者可从辅助治疗中获益，而CD133高表达患者除辅助治疗外还应给予新的治疗。我们的结果也为CSC假说提供了支持证据。
